PetVivo : CEO "getting great responses" to Lead Product
January 21, 2023 at 01:21 am
Share
PetVivo CEO "getting great responses" to Lead Product
Jan 20
Written By Gavin Colahan
PetVivo Holdings (NASDAQ:PETV) Inc CEO John Lai speaks to Proactive's Thomas Warner ahead of the company's appearance at the Ocala Equine Conference in Florida on 21-22 January. Lai gives a general update on the business heading into the new year and says he's been getting "getting great responses" to his company's Spryng technology, which aims to treated osteoarthritis in dogs and horses. #ProactiveInvestors#PETV#biotech#health#medicine#veterinary#invest#investing#investment#investor#stockmarket#stocks#stock#stockmarketnews
PetVivo Holdings Inc. published this content on 20 January 2023 and is solely responsible for the information contained therein. Distributed by Public, unedited and unaltered, on 21 January 2023 06:20:03 UTC.
PetVivo Holdings, Inc. is a biomedical device company. The Company is focused on the manufacturing, commercialization, and licensing of medical devices and therapeutics for animals. The Companyâs lead product Spryng with OsteoCushion Technology, is a veterinarian-administered, intraarticular injection for the management of lameness and other joint afflictions, such as osteoarthritis in dogs and horses. The Company is primarily engaged in the business of commercializing and licensing products in the veterinary market to treat and/or manage afflictions of companion animals, such as dogs and horses. Its products are derived from biomaterials that simulate a bodyâs cellular tissue by virtue of their reliance upon natural protein and carbohydrate compositions, which incorporate such tissue building blocks as collagen, elastin, and proteoglycans such as heparin. The Company has a pipeline of therapeutic devices for both veterinary and human clinical applications.
PETVIVO HOLDINGS, INC. 
